Remember that post-marketing trial? New study confirms many drugmakers don’t do them — half drag their feet
Earlier this month Sarepta confirmed to us that the post-marketing study the FDA required in their controversial OK for the Duchenne MD drug Exondys 51 — now on the market at $1 million a year — was years behind schedule.
But it’s right in line with the industry norm — which runs from slow to glacial.
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
